Clinical Guides
Gastric Cancer — Recognition, Staging and Management
A clinically focused guide to recognising, diagnosing and staging gastric adenocarcinoma and coordinating multimodal care in India, with explicit limits on foreign referral thresholds, biomarker-directed therapy and specialist prescribing.
MedNext Academy | 13 min read
Gastric Cancer — Recognition, Staging and Management
A clinically focused guide to recognising, diagnosing and staging gastric adenocarcinoma and coordinating multimodal care in India, with explicit limits on foreign referral thresholds, biomarker-directed therapy and specialist prescribing.
Summary
Gastric cancer most often means adenocarcinoma arising in the stomach, but the anatomical label also covers distinct diseases such as lymphoma, gastrointestinal stromal tumour and neuroendocrine neoplasia. Even among adenocarcinomas, cardia and non-cardia location, intestinal and diffuse histology, molecular biomarkers and hereditary syndromes alter risk and treatment. Chronic Helicobacter pylori-associated gastritis can progress through atrophy, intestinal metaplasia and dysplasia to non-cardia adenocarcinoma, whereas diffuse cancers may infiltrate the wall without forming an obvious ulcer or mass.
Recognition depends on symptom pattern and context. Progressive dysphagia, weight loss with upper abdominal pain or dyspepsia, iron-deficiency anaemia, early satiety, persistent vomiting, haematemesis or melaena, a palpable mass, Virchow node or ascites require investigation rather than repeated empiric acid suppression. Upper gastrointestinal endoscopy with multiple biopsies establishes histology. CT stages chest, abdomen and pelvis; endoscopic ultrasound and staging laparoscopy are used selectively when they will change curative planning.
Potentially curable gastric adenocarcinoma is discussed by a specialist multidisciplinary team. Treatment can combine gastrectomy with appropriate lymph-node dissection and perioperative systemic therapy; very early mucosal disease may be suitable for expert endoscopic resection. Advanced disease requires biomarker assessment, systemic therapy selected through a current oncology protocol, nutrition and symptom control. This guide is educational, does not prescribe a chemotherapy regimen, and remains quarantined following MedNext Clinical Team review.
How Common Is It?
The IARC Global Cancer Observatory's GLOBOCAN 2024 India fact sheet estimates 68,548 new stomach-cancer cases and 45,392 deaths in India in 2024. Stomach cancer ranked sixth by incident cases across both sexes and fifth by cancer deaths. Among males it ranked fourth by incident cases. These figures are modelled national estimates released in July 2026; they are not a replacement for state cancer-registry data, and they should not be converted into an individual's prognosis. Geographic variation within India is substantial and can reflect dietary patterns, H. pylori prevalence, tobacco exposure, genetics, diagnostic access and registry ascertainment.
Globally, incidence varies markedly by region and is generally higher in parts of East Asia, Eastern Europe and Latin America than in many Western populations. The distribution is also changing: distal non-cardia cancers have declined in several countries while cardia adenocarcinoma has become relatively more prominent in some populations. Most cases occur in later adulthood, but diffuse hereditary disease can present younger.
Mortality remains high because early gastric cancer may cause few specific symptoms and many patients present after local or metastatic spread. Burden is not an argument for indiscriminate endoscopy of every person with transient dyspepsia. It supports risk-sensitive referral, quality endoscopy and biopsy, H. pylori prevention strategies, nutrition support and access to multimodal cancer care. Local audit should track stage at diagnosis, pathology turnaround, completion of planned therapy and postoperative outcomes rather than case count alone.
Risk Factors
Helicobacter pylori is the most important established environmental cause of non-cardia gastric adenocarcinoma. Persistent infection can drive chronic active gastritis, gland loss, intestinal metaplasia, dysplasia and invasive cancer over years. Risk is also increased by smoking, high intake of salted or poorly preserved foods, low fruit and vegetable intake in some observational studies, chronic atrophic gastritis, pernicious anaemia, gastric adenomas, prior partial gastrectomy and selected occupational or radiation exposures. Treating confirmed H. pylori reduces future risk in studied populations, but eradication does not remove established atrophy or abolish cancer risk.
Host and tumour location matter. Gastro-oesophageal reflux disease and obesity are more strongly associated with cardia-region adenocarcinoma than with distal cancer. Epstein-Barr virus is linked to a molecular subset. A first-degree family history increases concern, and several inherited syndromes raise risk, including hereditary diffuse gastric cancer from pathogenic CDH1 or CTNNA1 variants, Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, juvenile polyposis and Li-Fraumeni syndrome.
Ask about relatives with diffuse gastric cancer, lobular breast cancer, multiple gastrointestinal cancers or unusually young diagnoses. Genetics evaluation is required before considering prophylactic gastrectomy; a negative routine endoscopy cannot safely exclude microscopic diffuse disease in a proven high-risk syndrome. Risk factors guide vigilance, not diagnostic certainty. Many infected people never develop cancer, and some patients have no recognised exposure. New alarm symptoms still require evaluation even after H. pylori eradication or years of proton-pump inhibitor use.
Diagnosis
History
Clarify dyspepsia, epigastric pain, early satiety, reduced appetite, postprandial fullness, nausea, persistent vomiting, dysphagia, odynophagia, haematemesis, melaena, fatigue and weight loss. Establish onset, progression and response to treatment rather than accepting a chronic label of acidity. Ask about H. pylori testing and eradication, peptic ulcer, prior gastric surgery, pernicious anaemia, smoking, alcohol, medicines that bleed or mask symptoms, and a three-generation cancer history. Dysphagia or obstruction changes urgency.
Examination
Record haemodynamic stability, performance status, weight trajectory, sarcopenia, pallor and dehydration. Examine for an epigastric mass, hepatomegaly, ascites, peritoneal signs and gastric succussion splash. Look for left supraclavicular lymphadenopathy, umbilical deposit, pleural effusion and signs of venous thrombosis or metastatic disease. A normal abdominal examination is common and cannot defer endoscopy when alarm features are present.
Investigations
Full blood count, iron studies, renal and liver function, albumin and coagulation support diagnosis and treatment planning but do not establish cancer. Upper gastrointestinal endoscopy with careful lesion documentation and adequate biopsies is the diagnostic test. Pathology defines histology and may require repeat sampling when infiltrative disease is suspected. CT chest, abdomen and pelvis assesses local and distant spread. Current guidelines recommends staging laparoscopy for potentially curable gastric cancer; peritoneal washings can detect occult spread. Endoscopic ultrasound is reserved for questions that change management, and PET-CT is selective because some gastric cancers are poorly FDG-avid. Advanced adenocarcinoma requires current biomarker testing, commonly including HER2, mismatch-repair or microsatellite-instability status and PD-L1, with additional targets dictated by locally available therapy.
Differential Diagnosis
Common benign disorders can mimic early gastric cancer. Functional dyspepsia, gastro-oesophageal reflux disease, H. pylori gastritis and peptic ulcer disease cause epigastric discomfort, nausea or early satiety. A response to antacid or proton-pump inhibitor treatment does not exclude malignancy. Gastric ulcers require adequate biopsy and healing assessment when clinically indicated because a malignant ulcer may initially look benign. Gastroparesis, gastric outlet obstruction from chronic ulcer disease, pancreatitis, biliary disease and medication injury are further alternatives.
The pathological differential changes management. Gastric lymphoma may arise in association with H. pylori or systemic lymphoid disease. Gastrointestinal stromal tumour is mesenchymal and requires morphology, immunohistochemistry and mutation-sensitive treatment rather than an adenocarcinoma pathway. Neuroendocrine neoplasms vary from indolent type 1 lesions related to autoimmune atrophic gastritis to aggressive poorly differentiated carcinoma. Metastases to stomach, pancreatic or colonic invasion and gastro-oesophageal junction cancers must be anatomically classified. Gastric tuberculosis, Crohn disease and inflammatory masses are relevant mimics in India, but presumed infection should not delay biopsy of a suspicious lesion.
Diffuse gastric cancer may cause linitis plastica with a rigid, poorly distensible stomach and deceptively superficial biopsies. Pernicious anaemia and autoimmune gastritis may coexist with neuroendocrine or adenocarcinoma risk. In a patient with weight loss, anaemia, vomiting or dysphagia, the diagnostic goal is not to choose the commonest benign label; it is to obtain endoscopy and tissue while also correcting bleeding, obstruction and malnutrition.
Management
All confirmed gastric adenocarcinomas should be reviewed by an upper gastrointestinal cancer multidisciplinary team. Immediate priorities include bleeding control, hydration, venous-thromboembolism assessment, gastric outlet obstruction, pain and nutrition. Resectability is not decided from one CT sentence: pathology, high-quality staging, operative fitness, nutritional reserve and the probability of a margin-negative oncological resection must be considered together. Staging laparoscopy is important for potentially curable disease because small peritoneal metastases may be occult on imaging.
Very early, node-negative mucosal lesions meeting strict histological and technical criteria may be treated by expert endoscopic resection with complete specimen assessment and surveillance. Most resectable cancers require subtotal or total gastrectomy according to tumour location and margins, with regional lymphadenectomy. Current guidelines advises considering D2 dissection for curative gastrectomy. Surgery should be performed in a specialist unit because leak, bleeding, pancreatic injury, nutritional failure and lymph-node quality depend on team experience and rescue capacity.
For fit patients having radical surgery, perioperative chemotherapy is a standard multimodal strategy in many protocols; postoperative treatment may be considered when preoperative therapy was not given. Advanced or recurrent disease is treated according to performance status, organ function, HER2, mismatch-repair or microsatellite status, PD-L1 and other validated targets, prior therapy and access. Endoscopic stenting, surgical bypass, radiotherapy, drainage, transfusion and palliative care can relieve obstruction, bleeding, pain or ascites. Every pathway needs specialist dietetic support before, during and after treatment.
Prescribing Information
Systemic anticancer therapy for gastric cancer is a specialist, biomarker- and stage-dependent prescription. Common backbones use a fluoropyrimidine with a platinum compound, sometimes in a multi-drug perioperative regimen. Advanced-disease treatment may add HER2-directed therapy, immune-checkpoint inhibition or another target-specific medicine when validated testing and the current local indication support it. Later-line options depend on previous exposure and performance status. Exact doses, cycles and combinations change with evidence and regulation and are deliberately not reproduced here.
Before treatment, verify histology, anatomical site, stage, HER2, mismatch-repair or microsatellite status, PD-L1 method where relevant, full blood count, renal and hepatic function, nutrition, neuropathy, cardiac history, infection risk and concomitant medicines. Fluoropyrimidines can cause mucositis, diarrhoea, cytopenias, hand-foot syndrome and potentially serious cardiotoxicity; severe dihydropyrimidine dehydrogenase deficiency markedly increases toxicity. Platinum agents cause nausea, cytopenias, neuropathy and organ-specific toxicity. Immune therapy can inflame endocrine organs, lung, bowel, liver, kidney or skin and requires rapid recognition rather than routine steroid self-treatment.
Supportive prescribing includes evidence-based antiemetics, analgesia, bowel care, thrombosis treatment, acid suppression when indicated and micronutrient replacement after gastrectomy. After total gastrectomy, lifelong vitamin B12 replacement is generally required; iron, folate, calcium and vitamin D require assessment and tailored replacement. Fever, rigors, chest pain, dyspnoea, uncontrolled diarrhoea or vomiting, bleeding, confusion or reduced urine output needs urgent oncology advice. Medication reconciliation should include herbal and non-prescription products because interactions and duplicated acid suppression are common.
When to Refer
Use an urgent suspected-cancer pathway for progressive dysphagia and for combinations of older age, weight loss and upper abdominal pain, reflux or dyspepsia that meet the adopted referral criteria. current guidelines currently recommends suspected-cancer referral for stomach cancer when there is dysphagia, or at age 55 and over when weight loss accompanies upper abdominal pain, reflux or dyspepsia. It also lists endoscopy indications for haematemesis, treatment-resistant dyspepsia, anaemia-related pain, thrombocytosis-associated symptoms and persistent nausea or vomiting. These are UK pathway rules, not Indian national thresholds; local Indian protocols and clinical judgement govern.
Confirmed cancer should be referred to a specialist upper gastrointestinal multidisciplinary service before definitive surgery. Expedited direct discussion is required for inability to swallow liquids, persistent vomiting, dehydration, active bleeding, symptomatic anaemia, gastric outlet obstruction, perforation, sepsis, rapidly declining performance or significant malnutrition. Emergency resuscitation must not wait for routine clinic scheduling. A patient with an endoscopic biopsy described as suspicious, inadequate or discordant with a linitis-plastica appearance needs coordinated repeat tissue acquisition rather than reassurance.
Refer to clinical genetics for diffuse gastric cancer at a young age, a family pattern of diffuse gastric or lobular breast cancer, or another recognised hereditary syndrome. The referral should transmit endoscopy images and report, pathology, CT and staging data, laboratory results, weight trajectory, comorbidity, prior abdominal surgery and current nutritional intake. Name a receiving centre and document who will review outstanding pathology; a generic instruction to seek oncology care is not a safe handover.
Red Flags
Dysphagia, haematemesis, melaena, progressive vomiting, unexplained iron-deficiency anaemia, marked weight loss, early satiety with reduced intake, an epigastric mass, Virchow node, ascites or jaundice are alarm findings. A new symptom pattern in later life carries more concern than longstanding intermittent dyspepsia, but age alone cannot exclude cancer. Persistent symptoms despite apparently adequate acid suppression require reassessment. Repeatedly renewing a proton-pump inhibitor without checking alarm features can mask progression and delay endoscopy.
Some presentations require emergency action. Haemodynamic instability, ongoing upper gastrointestinal bleeding, syncope, peritonism or free intraperitoneal air suggests major haemorrhage or perforation. Inability to retain fluids, visible gastric distension or a succussion splash with metabolic disturbance suggests outlet obstruction. Fever and hypotension after chemotherapy may represent neutropenic sepsis. Acute dyspnoea or unilateral leg swelling raises concern for venous thromboembolism. These conditions are treated and stabilised while cancer assessment continues.
During and after treatment, urgent concerns include anastomotic leak, abdominal sepsis, uncontrolled pain, severe diarrhoea, dehydration, febrile neutropenia, immune-related organ inflammation, bleeding and rapid nutritional deterioration. Post-gastrectomy dizziness, palpitations and diarrhoea after food may be dumping syndrome, but chest pain, collapse or severe abdominal pain must not be assigned that label remotely. Safety-net instructions should account for travel, language and out-of-hours access and specify where blood tests and oncology advice are available.
Indian Clinical Context
GLOBOCAN 2024 estimates 68,548 new stomach-cancer cases and 45,392 deaths in India, with higher incidence in males. India is heterogeneous: regional diets, tobacco use, H. pylori burden, genetic background, endoscopy access and registry completeness vary. A national estimate should not be used to claim uniform risk across states. Where high-quality endoscopy is scarce, alarm-symptom triage, adequate biopsy, complete reporting and direct referral become especially important. A report saying only gastric growth is not enough; location, extent, obstruction, photographs, number of biopsies and pathology status should travel with the patient.
No single Indian national document identified for this draft provides one complete, current pathway covering primary-care referral, surgical quality, biomarker testing and every systemic regimen. current guidelines and NG83 are therefore used for transparent recognition, staging and service principles, and NCI PDQ for current evidence synthesis, with explicit jurisdictional limits. Indian oncology centres and National Cancer Grid institutions may use resource-stratified local protocols. The receiving centre's current tumour-board and formulary decisions prevail.
Late presentation and undernutrition are common practical challenges. Weight, intake and symptoms should be assessed at first contact; dietetic support and enteral access planning should not wait until severe cachexia. Discuss travel, caregiver needs, lost wages, pathology cost, biomarker availability and public financing honestly. H. pylori testing and eradication are valuable prevention and ulcer-care measures but must not be sold as treatment for an established cancer. Use trained interpreters where possible, obtain informed consent for major surgery and avoid assuming that palliative care means withdrawal of active symptom treatment.
NMC Competency Mapping
The NMC 2024 surgery curriculum maps carcinoma stomach within competency SU28.8, which asks learners to describe and discuss aetiology, clinical features, investigations and principles of management alongside related upper gastrointestinal disease. A competent graduate should identify alarm symptoms, assess bleeding, obstruction and nutritional state, perform a structured abdominal and nodal examination, request or interpret the appropriate initial tests and refer confirmed or strongly suspected disease to a specialist service. Independent gastrectomy or chemotherapy prescribing is outside undergraduate competence.
Knowledge integration spans anatomy, pathology, microbiology, medicine, pharmacology and surgery. Learners should explain gastric lymphatic drainage, Virchow node and transcoelomic spread; distinguish intestinal-type gland-forming and diffuse poorly cohesive patterns; connect H. pylori to the atrophy-metaplasia-dysplasia sequence; and describe TNM staging. They should understand why endoscopic biopsy, CT, staging laparoscopy, nutrition and MDT assessment precede treatment. Surgical principles include tumour-location-based subtotal or total gastrectomy, clear margins, lymphadenectomy and recognition of postoperative complications.
Assessment can use a dyspepsia referral vignette, interpretation of an endoscopic ulcer report, an anaemia case, consent discussion or postoperative nutrition station. Learners should know that D2 lymphadenectomy is a specialist oncological procedure, not a larger operation to request indiscriminately. Professional practice includes timely escalation, accurate handover, respect for pathology uncertainty and avoidance of unsupported claims about screening, H. pylori or a universal chemotherapy regimen.
Key Exam Pearls for NEET PG
Helicobacter pylori is a major cause of non-cardia gastric adenocarcinoma and drives the Correa cascade: chronic gastritis, atrophy, intestinal metaplasia, dysplasia and carcinoma. Diffuse-type cancer is composed of poorly cohesive cells, may contain signet-ring cells, and can produce linitis plastica. CDH1 is central to hereditary diffuse gastric cancer. Gastric lymph follows named arterial stations to coeliac nodes; Virchow node is left supraclavicular, Sister Mary Joseph nodule is umbilical, Krukenberg tumour is ovarian metastasis, and a Blumer shelf is a rectal-examination clue to pelvic peritoneal deposit.
Endoscopy with multiple biopsies establishes diagnosis. CT stages distant and local disease; endoscopic ultrasound refines selected early local staging; staging laparoscopy detects occult peritoneal disease in potentially curable patients. Early mucosal lesions meeting strict criteria may undergo endoscopic resection. Resectable disease usually needs oncological gastrectomy with lymph-node dissection and multimodal therapy. Current guidelines advises considering D2 dissection in curative gastrectomy, but this is specialist surgery. Gastric cancer is staged by TNM, not by symptoms or one tumour marker.
Advanced adenocarcinoma requires biomarker-directed thinking: HER2, mismatch-repair or microsatellite instability, PD-L1 and other validated targets can alter systemic options. After total gastrectomy, vitamin B12 replacement is required because intrinsic-factor production is lost; iron and calcium-related deficiencies and dumping syndrome are also tested. Never accept symptom improvement on a proton-pump inhibitor as evidence against cancer when dysphagia, weight loss, bleeding, anaemia, vomiting or early satiety persists.
Frequently Asked Questions
Does persistent indigestion mean that a person has gastric cancer?
Usually not, because functional dyspepsia, reflux, gastritis and peptic ulcer are much more common. The concern rises when symptoms are new or progressive, especially with dysphagia, weight loss, early satiety, vomiting, bleeding or iron-deficiency anaemia. Improvement with acid suppression does not rule cancer out. Alarm patterns require endoscopy according to the adopted clinical pathway.
Can treating Helicobacter pylori cure an established gastric cancer?
No. H. pylori eradication can reduce future gastric-cancer risk in studied populations and treats H. pylori-associated gastritis or ulcer disease, but it does not replace cancer staging, surgery or systemic treatment once invasive gastric cancer is present. A person with alarm symptoms still needs endoscopy even if infection was treated successfully in the past.
Why is staging laparoscopy used when the CT scan looks operable?
Small peritoneal implants and malignant washings can be missed on cross-sectional imaging. Finding them can prevent a major gastrectomy that would not be curative and redirect care to systemic or symptom-focused treatment. Staging laparoscopy is therefore recommended for potentially curable gastric cancer when its result will guide management, rather than being an optional repetition of CT.
Will every patient with gastric cancer need the whole stomach removed?
No. The operation depends on tumour location, margins, stage and histology. Some very early lesions can be removed endoscopically, and distal cancers may be treated with subtotal gastrectomy when oncologically appropriate. Proximal, diffuse or extensive disease may require total gastrectomy, while metastatic disease may not benefit from radical resection. The specialist MDT decides after complete staging.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic